SAFC’s Supply Solutions business segment received a license for Beckman Coulter’s fast deprotection chemistry. The agreement covers Beckman Coulter’s acetyl-protected cytidine DNA- and 2'-O-methyl phosphoramidites for the synthesis of oligonucleotides. These chemistries collapse cleavage and deprotection timelines to mere minutes, while completely maintaining the integrity of synthesized DNA and RNA, according to SAFC.
SAFC is the first company licensed to the full range of these phosphoramidites, which will be produced at their Proligo® Reagents ISO 9001-certified manufacturing facility in Hamburg, Germany. The licensing agreement expands SAFC’s oligo synthesis reagents offer in the sector.
“Oligo therapeutics are now the focus of over 120 preclinical studies or clinical trials and the industry has seen investments of over $3.5 billion in the past four years,” explains Andreas Wolter, SAFC’s Proligo Reagents Managing Director.
“Our licensing agreement with Beckman Coulter provides customers with access to these key components in oligonucleotides synthesis. Use of fast deprotection technology, supported by proven high-quality and consistency of SAFC Proligo Reagents will benefit scientists across research, pharmaceutical and diagnostic applications.”